On Monday, Ideaya Biosciences Inc (NASDAQ: IDYA) opened higher 4.90% from the last session, before settling in for the closing price of $28.60. Price fluctuations for IDYA have ranged from $27.52 to $47.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 14.24% annually for the last half of the decade. Company’s average yearly earnings per share was noted -27.78% at the time writing. With a float of $76.56 million, this company’s outstanding shares have now reached $84.48 million.
In an organization with 124 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 64.98%, operating margin of -1600.08%, and the pretax margin is -1285.34%.
Ideaya Biosciences Inc (IDYA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ideaya Biosciences Inc is 9.37%, while institutional ownership is 92.04%. The most recent insider transaction that took place on Aug 26 ’24, was worth 3,016,500. Before that another transaction happened on May 29 ’24, when Company’s Chief Scientific Officer sold 28,500 for $36.24, making the entire transaction worth $1,032,884. This insider now owns 0 shares in total.
Ideaya Biosciences Inc (IDYA) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.46 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.49) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.78% per share during the next fiscal year.
Ideaya Biosciences Inc (NASDAQ: IDYA) Trading Performance Indicators
Check out the current performance indicators for Ideaya Biosciences Inc (IDYA). In the past quarter, the stock posted a quick ratio of 17.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 656.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.61 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Ideaya Biosciences Inc (IDYA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.69 million. That was inferior than the volume of 0.85 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 33.05%. Additionally, its Average True Range was 1.40.
During the past 100 days, Ideaya Biosciences Inc’s (IDYA) raw stochastic average was set at 14.67%, which indicates a significant decrease from 62.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.91% in the past 14 days, which was lower than the 50.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.96, while its 200-day Moving Average is $39.04. However, in the short run, Ideaya Biosciences Inc’s stock first resistance to watch stands at $30.99. Second resistance stands at $31.97. The third major resistance level sits at $33.45. If the price goes on to break the first support level at $28.53, it is likely to go to the next support level at $27.05. The third support level lies at $26.07 if the price breaches the second support level.
Ideaya Biosciences Inc (NASDAQ: IDYA) Key Stats
There are currently 84,481K shares outstanding in the company with a market cap of 2.57 billion. Presently, the company’s annual sales total 23,390 K according to its annual income of -112,960 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -39,570 K.
